{"name":"Vega Therapeutics, Inc","slug":"vega-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"VGA039","genericName":"VGA039","slug":"vga039","indication":"Treatment of type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"VGA039","genericName":"VGA039","slug":"vga039","phase":"phase_3","mechanism":"VGA039 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Treatment of type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNcU5DbE1HVXpfVVdCWkRUSUlNRkk2aHRPMF8yVHdWOXkzekxfRHlzODlfUGM3bVVHYllNaFdRNERRX2c1QlFQYkRPb201dkdhYkJXSHdNOXhvN2RZUlZMVjQ1MUFYUkVIdHlMd0pwTk9kWm8zVUM3Z2VER3VsclBIYl85dkRtSTBYSkFySQ?oc=5","date":"2025-09-30","type":"pipeline","source":"BioPharma Dive","summary":"Star raises another $125M for its blood disease drug - BioPharma Dive","headline":"Star raises another $125M for its blood disease drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOeERsdnpXOU1MWmZEZ2lZWWZBdGlHazdoLWZnSTBPaUtKRjJqV1l1dHpfSDZRM05RYnloTTFvOUo0ZDRwRHdMTkZCWWpOeFVRa1FQeWFvWUt0bkd3R3RjRGliTVo5UEZFLXBkaDFzTHRFRS1ua2puWW11UG1CTWgxdTJtdm9LUm1MVDRCZUJVQ21iTVVrX18yVmh3LXMzUDYzd2t6UzZBMFhLZFlpMjYwNjNXRkdvaHU2V053SVpPbFc3S1dOVHc?oc=5","date":"2025-09-30","type":"pipeline","source":"fiercebiotech.com","summary":"Star Therapeutics collects shiny $125M funding boost to push bleeding disorder prospect into orbit - fiercebiotech.com","headline":"Star Therapeutics collects shiny $125M funding boost to push bleeding disorder prospect into orbit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPdUg4SHl1eXh5Z01hZ1dYY0laZmEtZTEzUTYySldjTDlYU0lQSFRjVlI0THZFNEszaFBtblp6UU5kcFdrUFNnWEVVdWxFVU1qajZpMVZJNFJHUEpfLVEwdThHckVHcjBBOGVEWGlObzF0c2F6Q09naGJCT1JuQjlER0NRSTByQV9YUnh4c3hmVk01VXk2YWIxS201bUhNS2dRNm5jWTRtaUFFUm40Y3MycnZJdFVPYlROdDVrc2tjSG1Sa3Z0NzRfX09R?oc=5","date":"2025-07-11","type":"pipeline","source":"BioSpace","summary":"BrainXell, Inc. Appoints Katherine Vega Stultz as Chief Executive Officer and Board Director - BioSpace","headline":"BrainXell, Inc. Appoints Katherine Vega Stultz as Chief Executive Officer and Board Director","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQSHNqTk95OE5iZlNsa1o2TnBIc3cxeTlvZUFlZkwxLW1fNmg0NlhIbHFnYnBhRzE5b2FpcDFubWJ1bVN2SWJZV20wWkhnVGtscU93LUZjbjlJczJsSF9tak1PN0VNbDZxN0lmdU5xV2tYXzAtRDNPbks1UXFGSUNmSDcwNjFZczZtWlE?oc=5","date":"2023-09-05","type":"pipeline","source":"BioPharma Dive","summary":"Star Therapeutics adds another $90M to grow its galaxy of drug startups - BioPharma Dive","headline":"Star Therapeutics adds another $90M to grow its galaxy of drug startups","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxNTnBFOTFsMmM5WTlhS1hCME1lSlc5TFdxSUQ1dEZqX0hKQUR0eGRFRzMxeDlkSjZWeDExUU5VMnZTV2dmd1E3T0tmYU56eGhER25xM2ZxV1RjNjZuUUlQOXlUTEIwaW1PU3d1UzF4Tzh6UXhXS1BiMFRNVjZhYXhWeEQzS3diWHdlcnctbnA2Skh1QlNGX2N5Q2lHNlpiRFB0dUlTYS13N0VoYkVlcjRsNFd5UWpzS2ozdUJPV1JMOXA2ZDFDc1FuUDIza2d0YzFjVWx2QnVneFREcWx2NTNhTkM3Q3BCTHVqUEs3SFFlVFJuWlk5cnJvWFotOGRGcnh2ZDdodUc5bnNXRC1fbGc0UnAtMV9zT1hIMEhyanotOFIzOVBq?oc=5","date":"2023-09-05","type":"pipeline","source":"businesswire.com","summary":"Star Therapeutics Raises $90 Million Financing to Accelerate Its Pipeline of Novel Antibody Therapies and Growth of Its Portfolio Companies - businesswire.com","headline":"Star Therapeutics Raises $90 Million Financing to Accelerate Its Pipeline of Novel Antibody Therapies and Growth of Its ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxNY3VOWndFZVBSeFE4VjRLb1c0amZOV2tvQ0ZvMlBNUENwRmw2WjBtSEJST2tkRngxRGFGUXRQM2xQdVQydzNIQ0dUb3RIbmJMZjJkcnczMmNtVTZjQ183UmFyVnFYNnozODdUX2wwU0hLdGZvd09pY1FGYnlwYzBTaDJrc25hVG9lamFuODVWSXJCWXpva2ROQl93VERnZUVRZUcyeC1iMlNVRWdmSUxlNDA4ZHZEWTAyUUM4RFRFZURZQW5Jd0RsUDBxLWpRbldrVFA4NERNWVdldnRwMEdQRUNNRWgzNnRueGc2QkxKTkpGVXhydEVOdG13?oc=5","date":"2023-05-23","type":"regulatory","source":"businesswire.com","summary":"Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease - businesswire.com","headline":"Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPU29CMUprcDgyRy1kS2t2TnNYc0xPWk5seHR6dXMybnpCOXV0aGJqSmdpTHFwblVqWHRhN1VNZFlYYkIwTlBCOTZqZEwwaDJPZDViZHJIc0dmZ1Q4V3p4cTVXYWJvY3pSZDhxa2hOXy1zMm1scWhBX3c4VkRqc3g5bWoydm9uRXd2OU5TSkc2OWdnZkttTW9PdU1LRnY4UFZmMW1KRWU2amhKZTNUb282SWZocjZvT2c3WDBrS2pCbEQ3blQtcVlPVlhOM1M3RW9BX1k5ek9wSDdxdU1SNVljQ2dZNWhERktTLXZtdG9vN1dLczZPTzhqZElKNmFzTlFldUlBTk1QdHQ?oc=5","date":"2023-04-05","type":"trial","source":"businesswire.com","summary":"Vega Therapeutics Initiates Clinical Trial Program for VGA039, a First‑in‑Class Antibody Therapy for von Willebrand Disease - businesswire.com","headline":"Vega Therapeutics Initiates Clinical Trial Program for VGA039, a First‑in‑Class Antibody Therapy for von Willebrand Dise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNWHJOSVNrY2YyQlZNQmxzeWxqN1RWeXA2Zm02T0tVYkJ0NE42MnotRzhzQWVuV3NjUl9RNFZFUlhmM2dqeGlJQUZtVnh3QWhIR3N0MjVwLTZ3ZkpsVnVQbE8wSVBfaF9lY3MzNFdlbUM4LUo3eF9nYXhLOEp5eWd2a0hINlc2T181anZqVTVfLXViaENvcm44eUFIcGFLVkttM2tmZVR2WW5PLWs2MFJUUjREaXlGR2N3SktETktVdWFyMHMw?oc=5","date":"2023-01-09","type":"trial","source":"Ophthalmology Times","summary":"Ocuphire Pharma enrolls first patient in VEGA-2 phase 3 trial for presbyopia treatment - Ophthalmology Times","headline":"Ocuphire Pharma enrolls first patient in VEGA-2 phase 3 trial for presbyopia treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNRjhCMTh2cWhEbE83REhTbnE0R0l6UVA2dE55QWJLdW1mTHFSWUItQjBtTUZJMW9UY0hIdmF3cENDVkhGaW1nU2JjTG5ieVFJMmhoOW5Gc2NlQnd5R0wyNDI5bmpwTU1kWmt4cTV1TlRHY01QXzV1T3hiUHdnaGV6OTJfOU02Z05MU1EtdV9VaHl1UGF4LTI5SkE4N0lyWGc?oc=5","date":"2022-12-27","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Rising Star: Vega Targets Rare Blood Disorders with Antibodies - Genetic Engineering and Biotechnology News","headline":"Rising Star: Vega Targets Rare Blood Disorders with Antibodies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNQzAzUnlldWNpb25XVHA1VFJudGI1Z0lGZWN3ZHZCMENmOWh2R1h4UFp5cFVDdzdxX052ZWFidmRzN1I4LUJCSnAzVS0zcEJQeUplNXZZMmN2YnBveG1vRXFYbkFaZDhjZ2ZEUjFKUU5pZ25JZEEtbVlQY1o2TnNUbTV3OFBXTlExMEJrTlptcjFnTUFF?oc=5","date":"2022-12-06","type":"pipeline","source":"BioPharma Dive","summary":"Star Therapeutics launches Vega, growing its galaxy of drug startups - BioPharma Dive","headline":"Star Therapeutics launches Vega, growing its galaxy of drug startups","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQVGxCQU1NNWVqUWxtTGNyYmc2NE5BRmRDdkQtdXBVbXdmWElxUndWNm4wSGZTdDQ4OUtPZHliREh4STFId1ZRVlNPY25QTU00RWxnbFVSbE9sV2Q3ZVZuV1Y3cmp0bjc4T1J1OENvZWluN05mRWhXTi1kc0M5Um9vd05OV0FVZDJrdEhfemhtbmY1QldwNmNkanFrVkt5U01OVHdDRHVVSG51QjY4WXNHd1ptN3VmMnliMFVpcg?oc=5","date":"2022-12-06","type":"pipeline","source":"BioWorld News","summary":"Another star is born: Vega Therapeutics targets protein S for bleeding disorders - BioWorld News","headline":"Another star is born: Vega Therapeutics targets protein S for bleeding disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOcTVialNPQVZGYTRsU0duOFRGSHdQQmNFZ05pdkFjNE1rRnQ2d2VZaENiY2ZzYTQ3cUNWcExZMUdNeGNsQlNSN2FPUXIzX0Rob2w2ZHkwQUdhaUxhcmZwM0VXZ19XZGU3YXhQdFRoQ1NGRkVtSkhCV2hqZ2hzQzJMaUZoV1BIZmJpLXpNZWtUVFJ4QkRKWmVwbEZDRTRjSWlyVHlSazI1SjJXbzFWVVhlTTI5eXVvS1ZqeElhOEpkSUdZOFM4WVZTVmZkQQ?oc=5","date":"2022-11-23","type":"pipeline","source":"Healio","summary":"VEGA: Guselkumab plus golimumab achieved higher clinical remission rates in UC - Healio","headline":"VEGA: Guselkumab plus golimumab achieved higher clinical remission rates in UC","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}